Gelexir Healthcare Ltd, Manchester, UK, is introducing a novel, non-surgical procedure for the treatment of Chronic Lower Back Pain (CLBP) caused by Degenerative Disc Disease (DDD).
Gelexir Healthcare, originating from the University of Manchester, develops a novel approach which addresses DDD at an early stage before the onset of irreversible disc degeneration of both the nucleus pulposus and annulus fibrosis material.
Gelexir expands with the opening of a French subsidiary, incubated at Ecole Polytechnique, the #1 French Engineering school.
Gelexir has successfully been audited by Lloyd Register Quality Assurance and obtained the ISO 13485 certification of its R&D and Manufacturing organisation.
Gelexir is proud to announce that Innovate UK, the UK’s innovation agency, granted funding to help the company develop its second product, a gel based solution to address painful Osteoarthritic finger and other small joints for the patients to minimise the pain and improve the range of motion. The program starts in September 2017.
Gelexir is proud to announce the USPTO granted its Microgel Particle patent (US9242028 B2) in January 2016. This decision is important as it strengthens the patent portfolio owned by the company. The Microgel Particle patent has already been granted in Europe, Japan, Korea, Canada, Australia. The Microgel Compositions patent is progressing well through the PCT process WO 2011/101684.
Gelexir highlighted in the Special issue from MedTech Strategist:
The MedTech Strategist features detailed profiles of 20 emerging medical technology companies identified by our seasoned editorial team as poised to impact the device space. Include Gelexir Healthcare: Bridging the Gap in Degenerative Disc Disease – click here for more info